If you forgot to take Quetiapina MABO
If you forget to take a dose, take it as soon as you remember. If it is almost time to take the next dose, wait until then. Do not take a double dose to make up for the missed dose.
If you interrupt the treatment with Quetiapina MABO
If you stop taking Quetiapina MABO abruptly, you may be unable to sleep (insomnia), or you may feel nausea, or you may experience headaches, diarrhea, vomiting, dizziness, or irritability. Your doctor may suggest reducing the dose gradually before stopping treatment.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Very rare side effects (may affect up to 1 in 10,000 people):
Side effects not known (frequency cannot be estimated from available data):
The class of medicines to which Quetiapine MABO belongs may cause heart rhythm problems that can be serious and, in severe cases, fatal.
Some side effects are only observed when a blood test is performed. These include changes in the amount of certain fats (triglycerides and total cholesterol) or blood sugar, changes in the amount of thyroid hormones in the blood, increased liver enzymes, decreases in the number of certain types of blood cells, decreases in the number of red blood cells, increased creatine phosphokinase in the blood (a substance found in muscles), decreases in the amount of sodium in the blood, and increases in the amount of prolactin hormone in the blood. Increases in prolactin hormone may, in rare cases, lead to:
Your doctor may ask you to have blood tests from time to time.
Side effects in children and adolescents
The same side effects that may occur in adults may also occur in children and adolescents.
The following side effects have been observed more frequently in children and adolescents or have not been observed in adults:
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for Pharmacovigilance of Medicines for Human Use:https://www.notificaram.es.
By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Store in the original packaging to protect it from moisture.
This medication does not require any special storage temperature.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Medications should not be disposed of through drains or in the trash. Dispose of the packaging and medications you no longer need at the SIGRE collection pointat the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medications you no longer need. By doing so, you will help protect the environment.
Composition of Quetiapina MABO prolonged-release tablets
Appearance of Quetiapina MABO prolonged-release tablets and content of the container
The tablets are brown, oblong, biconvex, film-coated, and have “Q 50” engraved on one face.
They are presented in aluminum/PVC/PVDC blisters, in containers of 60 tablets.
Marketing authorization holder
MABO-FARMA, S.A.
Calle Vía de los Poblados, 3, Edificio 6
28033 Madrid,
Spain.
Responsible for manufacturing
Merckle GmbH
Ludwig-Merckle Strasse 3
D-89143 Blaubeuren-Weiler
Germany
or
Teva UK
Brampton Road, HampdenPark, Eastbourne, East Sussex, BN22 9AG
United Kingdom
Last review date of the leaflet: June 2024
The detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.